PTS Diagnostics' Patent Enforcement Against Jant Pharmacal Gains Momentum

PTS Diagnostics’ Patent Enforcement Against Jant Pharmacal Gains Momentum

United States International Trade Commission opens investigation of Jant Pharmacal Corporation’s LipidPlus Meter and LipidPlus Profile test strips

Indianapolis, IN – Nov. 6, 2015 – PTS Diagnostics’ patent infringement enforcement efforts against Jant Pharmacal Corp. gained significant momentum today as the U.S. International Trade Commission (ITC) instituted an investigation of Jant and its suppliers: Infopia America, LLC and Infopia Co., Ltd. of South Korea (Infopia).

The ITC Press Release may be viewed online at

The ITC is an independent U.S. federal agency charged by Congress to investigate unfair trade practices that impact U.S. domestic industries. It has announced it will investigate Jant following a review of PTS Diagnostics’ allegations that the cholesterol test strips that include an HDL test and meters that Jant and Infopia are importing into and selling in the U.S. infringe PTS Diagnostics’ U.S. patent no. 7,087,397.

PTS Diagnostics’ CardioChek® family of lipid analyzers and PTS Panels® test strips are made in the U.S. The products that are the subject of the ITC investigation include Jant’s LipidPlus Meter and LipidPlus Profile test strips. PTS Diagnostics has requested that the ITC prohibit Jant and Infopia from importing into and selling in the U.S. any blood cholesterol testing products that infringe PTS Diagnostics’ patent. If the ITC agrees, it will enter an order excluding Jant’s products.

“We are very proud of how the healthcare industry has embraced our CardioChek lipid measurement system. The CardioChek family of products has screened more than 120 million patients worldwide,” said Robert Huffstodt, President and CEO of PTS Diagnostics. “PTS Diagnostics remains committed to protecting ourselves against this and any future patent infringements.”

Recognizing the strong connection between heart attack, stroke, and diabetes, CardioChek analyzers provide rapid point-of-care blood-chemistry values and measurements to help identify at-risk individuals. As one of the fastest, most cost-efficient and user-friendly analyzers on the market today, CardioChek systems accurately test lipid profile and glucose simultaneously with one fingerstick. In as little as 90 seconds, they provide on-site results with similar accuracy to clinical laboratories.

PTS Diagnostics’ PTS Panels lipid test strips measure total cholesterol, HDL cholesterol, and triglycerides, calculate LDL cholesterol and TC/HDL ratio, and do not require refrigeration. The accompanying meter is handheld, battery-operated, and compact and lightweight, making it easy to transport and store. CardioChek systems are CLIA-waived and meet NCEP guidelines for accuracy and precision. The CardioChek Plus analyzer offers simultaneous testing of lipid profile and glucose, has wireless communication capabilities, and is CRMLN-certified for total cholesterol and HDL cholesterol testing.

PTS Diagnostics expects that the ITC will conduct a hearing in its investigation of Jant and Infopia’s importation of cholesterol test strips that include an HDL panel and meters in 2016.

About PTS Diagnostics PTS Diagnostics is an innovative point-of-care diagnostics solutions provider that’s signature products include the CardioChek® lipid analyzer and the A1CNow® family of products. The CardioChek family of products have screened more than 120 million patients worldwide while the A1CNow product line works to enable people to lead healthier lives through ongoing management of diabetes. Together these products help identify individuals with cardiometabolic syndrome, a cluster of conditions that increase risks of developing cardiovascular disease or diabetes

Headquartered in Indianapolis, Indiana, PTS Diagnostics designs, manufactures, distributes and markets products for distribution in more than 135 countries around the world. For more information, visit or contact Tom Wiser at 317- 870-5610 or

MKG001805 Rev. 0 11/15